MBRX – Moleculin Biotech Inc
MBRX — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
3.62
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
EPS Last/This Y
-92.83
EPS This/Next Y
10.75
Price
2.41
Target Price
21
Analyst Recom
1
Performance Q
-38.21
Upside
-60,674.7%
Beta
1.73
Ticker: MBRX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | MBRX | 1.96 | N/A | N/A | 0 |
| 2026-03-10 | MBRX | 1.96 | N/A | N/A | 0 |
| 2026-03-11 | MBRX | 2.03 | N/A | N/A | 0 |
| 2026-03-12 | MBRX | 2.02 | N/A | N/A | 0 |
| 2026-03-13 | MBRX | 2.05 | N/A | N/A | 0 |
| 2026-03-17 | MBRX | 2.12 | N/A | N/A | 0 |
| 2026-03-18 | MBRX | 2.08 | N/A | N/A | 0 |
| 2026-03-20 | MBRX | 2.04 | N/A | N/A | 0 |
| 2026-03-25 | MBRX | 2.49 | N/A | N/A | 0 |
| 2026-03-26 | MBRX | 2.41 | N/A | N/A | 0 |
| 2026-03-27 | MBRX | 2.41 | N/A | N/A | 0 |
| 2026-03-30 | MBRX | 2.21 | N/A | N/A | 0 |
| 2026-03-31 | MBRX | 2.28 | N/A | N/A | 0 |
| 2026-04-01 | MBRX | 2.2 | N/A | N/A | 0 |
| 2026-04-06 | MBRX | 2.35 | N/A | N/A | 0 |
| 2026-04-07 | MBRX | 2.44 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | MBRX | 1.98 | - | 24.6 | -132.00 |
| 2026-03-10 | MBRX | 1.96 | - | 24.2 | -132.00 |
| 2026-03-11 | MBRX | 2.01 | - | 23.9 | -132.00 |
| 2026-03-12 | MBRX | 2.04 | - | 24.2 | -132.00 |
| 2026-03-13 | MBRX | 2.10 | - | 23.9 | -132.00 |
| 2026-03-17 | MBRX | 2.13 | - | 23.8 | -132.00 |
| 2026-03-18 | MBRX | 2.06 | - | 1.7 | -132.00 |
| 2026-03-19 | MBRX | 2.08 | - | -5.0 | -132.00 |
| 2026-03-20 | MBRX | 2.05 | - | -5.0 | -132.00 |
| 2026-03-23 | MBRX | 2.09 | - | -4.1 | -132.00 |
| 2026-03-24 | MBRX | 2.26 | - | -16.3 | -132.00 |
| 2026-03-25 | MBRX | 2.48 | - | -16.3 | -132.00 |
| 2026-03-26 | MBRX | 2.40 | - | -9.4 | -132.00 |
| 2026-03-27 | MBRX | 2.43 | - | -6.0 | -132.00 |
| 2026-03-30 | MBRX | 2.23 | - | -6.3 | -121.25 |
| 2026-03-31 | MBRX | 2.29 | - | -11.5 | -121.25 |
| 2026-04-01 | MBRX | 2.22 | - | -13.8 | -121.25 |
| 2026-04-02 | MBRX | 2.29 | - | -13.9 | -121.25 |
| 2026-04-06 | MBRX | 2.33 | - | -13.1 | -121.25 |
| 2026-04-07 | MBRX | 2.41 | - | -16.7 | -121.25 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | MBRX | 0.00 | 3.15 | 14.57 |
| 2026-03-10 | MBRX | 0 | 3.15 | 14.57 |
| 2026-03-11 | MBRX | 0 | 3.15 | 6.31 |
| 2026-03-12 | MBRX | 0 | 3.15 | 6.31 |
| 2026-03-13 | MBRX | 0 | 3.15 | 6.31 |
| 2026-03-18 | MBRX | 0 | 1.70 | 6.31 |
| 2026-03-19 | MBRX | 0 | 1.70 | 6.31 |
| 2026-03-20 | MBRX | 0 | 1.70 | 6.31 |
| 2026-03-23 | MBRX | 0 | 1.56 | 6.31 |
| 2026-03-24 | MBRX | 0 | 1.56 | 6.31 |
| 2026-03-25 | MBRX | 0 | 1.56 | 3.62 |
| 2026-03-26 | MBRX | 0 | 1.56 | 3.62 |
| 2026-03-27 | MBRX | 0 | 1.56 | 3.62 |
| 2026-03-30 | MBRX | 0 | 1.56 | 3.62 |
| 2026-03-31 | MBRX | 0 | 1.56 | 3.62 |
| 2026-04-01 | MBRX | 0 | 1.56 | 3.62 |
| 2026-04-02 | MBRX | 0 | 1.56 | 3.62 |
| 2026-04-06 | MBRX | 0 | 1.56 | 3.62 |
| 2026-04-07 | MBRX | 0 | 1.56 | 3.62 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-1.66
Avg. EPS Est. Next Quarter
-1.46
Insider Transactions
Institutional Transactions
1.56
Beta
1.73
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
4
Growth Score
19
Sentiment Score
26
Actual DrawDown %
99.8
Max Drawdown 5-Year %
-99.9
Target Price
21
P/E
Forward P/E
PEG
P/S
P/B
0.51
P/Free Cash Flow
EPS
-41.71
Average EPS Est. Cur. Y
-121.25
EPS Next Y. (Est.)
-110.5
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.41
Return on Equity vs Sector %
-251.8
Return on Equity vs Industry %
-235.3
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
-16.7
◆
MBRX
Healthcare
$2.41
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
48.5
Range 1M
84.9%
Sup Dist
5.8%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
82.5%
EPS NY
22.8%
52W%
2.3%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+771.4% upside
Upside
+771.4%
Quality
4
Moleculin Biotech, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 17
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.
MBRX
Latest News
—
Caricamento notizie per MBRX…
stock quote shares MBRX – Moleculin Biotech Inc Stock Price stock today
news today MBRX – Moleculin Biotech Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MBRX – Moleculin Biotech Inc yahoo finance google finance
stock history MBRX – Moleculin Biotech Inc invest stock market
stock prices MBRX premarket after hours
ticker MBRX fair value insiders trading